In a filing, Esperion Therapeutics Inc revealed its General Counsel Looker Benjamin unloaded Company’s shares for reported $7398.0 on Jun 17 ’25. In the deal valued at $1.15 per share,6,422 shares were sold. As a result of this transaction, Looker Benjamin now holds 401,241 shares worth roughly $0.45 million.
Then, Koenig Sheldon L. sold 30,474 shares, generating $33,796 in total proceeds. Upon selling the shares at $1.11, the President and CEO now owns 1,541,488 shares.
Before that, Halladay Benjamin sold 7,229 shares. Esperion Therapeutics Inc shares valued at $8,328 were divested by the Chief Financial Officer at a price of $1.15 per share. As a result of the transaction, Halladay Benjamin now holds 474,473 shares, worth roughly $0.53 million.
Goldman initiated its Esperion Therapeutics Inc [ESPR] rating to a Neutral in a research note published on December 18, 2024; the price target was $4. A number of analysts have revised their coverage, including Cantor Fitzgerald’s analysts, who began to cover the stock in mid December with a ‘”an Overweight”‘ rating. BofA Securities also remained covering ESPR and has decreased its forecast on June 20, 2024 with a “an Underperform” recommendation from previously “Neutral” rating. BofA Securities revised its rating on January 03, 2024. It rated ESPR as “a Neutral” which previously was an “a Buy”.
Price Performance Review of ESPR
On Monday, Esperion Therapeutics Inc [NASDAQ:ESPR] saw its stock fall -5.13% to $1.11. Over the last five days, the stock has gained 11.71%. Esperion Therapeutics Inc shares have fallen nearly -52.56% since the year began. Nevertheless, the stocks have fallen -49.55% over the past one year. While a 52-week high of $3.94 was reached on 01/14/25, a 52-week low of $0.69 was recorded on 05/15/25.
Levels Of Support And Resistance For ESPR Stock
The 24-hour chart illustrates a support level at 1.0800, which if violated will result in even more drops to 1.0500. On the upside, there is a resistance level at 1.1600. A further resistance level may holdings at 1.2100.
How much short interest is there in Esperion Therapeutics Inc?
A steep rise in short interest was recorded in Esperion Therapeutics Inc stocks on 2025-06-13, dropping by -3.83 million shares to a total of 24.11 million shares. Yahoo Finance data shows the prior-month short interest on 2025-05-15 was 27.95 million shares. There was a decline of -15.89%, which implies that there is a negative sentiment for the stock.
